Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) EPS (Basic) (2019 - 2025)

Goldenwell Biotech (GWLL) has disclosed EPS (Basic) for 6 consecutive years, with -$0.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, EPS (Basic) rose 28.92% year-over-year to -$0.0, compared with a TTM value of -$0.0 through Sep 2024, up 28.92%, and an annual FY2023 reading of -$0.0, up 88.09% over the prior year.
  • EPS (Basic) was -$0.0 for Q3 2024 at Goldenwell Biotech, up from -$0.0 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.0 in Q2 2020 and bottomed at -$0.01 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$0.0, with a median of -$0.0 recorded in 2023.
  • The sharpest move saw EPS (Basic) crashed 14209.11% in 2021, then surged 97.74% in 2023.
  • Year by year, EPS (Basic) stood at -$0.0 in 2020, then crashed by 768.79% to -$0.0 in 2021, then plummeted by 2849.03% to -$0.01 in 2022, then soared by 97.74% to -$0.0 in 2023, then decreased by 20.99% to -$0.0 in 2024.
  • Business Quant data shows EPS (Basic) for GWLL at -$0.0 in Q3 2024, -$0.0 in Q2 2024, and -$0.0 in Q1 2024.